Global Molecular Diagnostics Market - Focus on Infectious Diseases (HPV/Chlamydia/Gonorrhoea) & Genetic Testing (HLA) - Industry Outlook 2022

  • ID: 3920464
  • Report
  • Region: Global
  • 73 Pages
  • Rockville Research
1 of 6
The Global Molecular Diagnostics Market is Estimated to be Valued at US$ 6.7 Billion in 2016 and Projected to Reach US$ 11.4 Billion by 2022

FEATURED COMPANIES

  • Hologic Inc
  • Novartis AG
  • Qiagen NV
  • Roche Holdings
  • MORE
According to the new report “Global Molecular Diagnostics Market - Focus on Infectious Diseases (HPV/Chlamydia/Gonorrhoea) & Genetic Testing (HLA) - Industry Outlook 2022”, there has been unprecedented rise in sexually infected diseases such as Chlamydia and Gonorrhoea, particularly in the US. CT/NG is most prevalent sexually transmitted diseases (STD) in the US with consistent rise in the number of Chlamydia and Gonorrhoea cases. The Government has also recommended regular screening for patients belonging to two of the major segments of the molecular diagnostics market: HPV and CT/NG.

The report “Global Molecular Diagnostics Market - Focus on Infectious Diseases (HPV/Chlamydia/Gonorrhoea) & Genetic Testing (HLA) - Industry Outlook 2022” provides an in-depth analysis of global molecular diagnostics market which is estimated to be valued at US$ 6.7 billion in the year 2016 and projected to reach US$ 11.4 billion by 2022, growing at a CAGR of 9.3% in the period 2016-22. The report focuses on Infectious Diseases (HPV/Chlamydia/Gonorrhoea) & Genetic Testing (HLA). The infectious diseases segment dominates the molecular diagnostics market by application with HPV dominating in virology segment and CT/NG in bacteriology segment. It provides details on current and forecasted scenario of each of aforementioned diseases.

Growth of the market is driven by prevalence of reproductive infectious diseases such as Chlamydia and Gonorrhoea, surge in various types of oncology diagnostics, ageing population and government’s mandate on regular screening of HPV and CT/NG. However, growth of the industry is incumbent due to ambiguity in relation to reimbursement guidelines and presence of complex regulatory framework. Global Molecular Diagnostics market is dominated by few major companies, of which Roche Holding, Novartis AG, Hologic Inc., and Qiagen NV have been covered in the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Hologic Inc
  • Novartis AG
  • Qiagen NV
  • Roche Holdings
  • MORE
1. Executive Summary

2. Research Methodology

3. Introduction
3.1.1 History of Molecular Diagnostics
3.1.2 Molecular Diagnostics vs. Conventional diagnostics
3.1.3 Types of Molecular Diagnostics

4. Molecular Diagnostic Market
4.1 Global Molecular Diagnostics Market Analysis
4.1.1 Market Size by Value (Actual & Forecasted)
4.2.1 Market Share by Segment
4.2.2 Market Share by Discpline
4.2.3 Market Share by Competitors
4.2.4 Market Share by Region

5. Global Molecualr Diagnostics Market Segmentation
5.1 Clinical Infectious Disease Segment
5.1.1 Virology Segment - Human Papilloma virus (HPV) Testing Market
5.1.1.1 Market Size by Value (Actual & Forecasted)
5.1.1.2 Market Size by Volume (Actual & Forecasted)
5.1.1.3 Market Share by Region (Actual & Forecasted)
5.1.1.4 Market Share by Competitors
5.2 Bacteriology - CT/NG Testing Market
5.2.1 Market Size by Value (Actual & Forecasted)
5.2.2 Market Size by Volume (Actual & Forecasted)
5.2.3 Market Share by Region (Actual & Forecasted)
5.2.4 Market Share by Competitors
5.3 Genomics Testing Market - HLA Testing Market
5.3.1 Market Size by Value (Actual & Forecasted)
5.3.2 Human Leukocyte Antigen (HLA) Testing Market
5.4 Blood Donor Screening Segment

6. Global Molecular Diagnostics Market Dynamics
6.1 Market Trends & Developments
6.1.1 Strategic Alliances
6.1.2 Next Generation Sequencing in Clinical Molecular Diagnostics
6.2 Growth Drivers
6.2.1 Surge in Oncology Diagnostics
6.2.2 Prevalence of Reproductive Infectious Disease
6.2.3 Growing geriatric population
6.2.4 Government’s mandate on regular screening of HPV and CT/NG
6.3 Challenges
6.3.1 Complex Regulatory Framework
6.3.2 Lack of Clarity on Reimbursement

7. Competitive Landscape

8. Company Profiles
8.1 Roche Holding AG
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategies
8.2 Novartis AG
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategies
8.3 Qiagen NV
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategies
8.4 Hologic Inc
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategies

List of Figures:
Figure 1: History of Molecular Diagnostics
Figure 2: Types of Molecular Diagnostics
Figure 3: Understanding Molecular Diagnostics
Figure 4: Global Molecular Diagnostics Market Size by Value, 2006-15 (US$ Billions)
Figure 5: Global Molecular Diagnostics Market Size by Value Forecasted, 2016E-22E (US$ Billions)
Figure 6: Global Molecular Diagnostics Market Share by Application (2016E)
Figure 7: Global Molecular Diagnostics Market Share by Discipline (2016E)
Figure 8: Global Molecular Diagnostics Market Share by Competitors (2015)
Figure 9: Global Molecular Diagnostics Market Share by Region (2015)
Figure 10: Global HPV Market Size by Value, 2010-15 (US$ Millions)
Figure 11: Global HPV Market Size by Value Forecasted, 2016E-22E (US$ Millions)
Figure 12: Global HPV Market Size by Volume, 2010-15 (Million units)
Figure 13: Global HPV Market Size by Volume Forecasted, 2016E-20E (Million units)
Figure 14: Global HPV Market Share by Region, 2010-15 (%)
Figure 15: Global HPV Market Share by Region Forecasted, 2016E-22E (%)
Figure 16: Global HPV Market Share by Competitors, 2010-15 (%)
Figure 17: Global CT/NG Testing Market Size by Value, 2011-15 (US$ Millions)
Figure 18: Global CT/NG Testing Market Size by Value Forecasted, 2016E-22E (US$ Millions)
Figure 19: Global CT/NG Testing Market Size by Volume, 2011-15 (Million units)
Figure 20: Global CT/NG Testing Market Size by Volume Forecasted, 2016E-22E (Million units)
Figure 21: Global CT/NG Testing Market Share by Region, 2011-15 (%)
Figure 22: Global CT/NG Testing Market Share by Region Forecasted, 2016E-22E (%)
Figure 23: Global CT/NG Market Share by Competitors, 2010-15 (%)
Figure 24: Global CT/NG Market Share by Competitors Forecasted, 2016E-22E (%)
Figure 25: Global Genetic Testing Market Size by Value, 2007-15 (US$ Billions)
Figure 26: Global Genetic Testing Market Size by Value Forecasted, 2016E-22E (US$ Billions)
Figure 27: Global Human Leukocyte Antigen (HLA) Testing Market Size by Value, 2011-15 (US$ Million)
Figure 28: Global Human Leukocyte Antigen (HLA) Testing Market Size by Value Forecasted, 2016E-22E (US$ Million)
Figure 29: Global Molecular Diagnostics Blood Screening Market Size by Value, 2011-15 (US$ Millions)
Figure 30: Global Molecular Diagnostics Blood Screening Market Size by Value Forecasted, 2016E-22E (US$ Millions)
Figure 31: The US Oncology Market by Segments, 2014-20E (Thousands)
Figure 32: Incidence of Chlamydia and Gonorrhea in the US, 2000-2012 (Thousands)
Figure 33: Global Ageing Population (65 years and above), 2009-15 (Millions)
Figure 34: Molecular Diagnostic Revenue by Company, 2015 (US$ Billions)
Figure 35: Global Molecular Diagnostic Players Growth Rate (2015)
Figure 36: Molecular Diagnostic System Installed Base in US Hospitals as % of Total Instruments (March’2015)
Figure 37: Roche Holding Revenue by Business Segment (FY2015)
Figure 38: Roche Holding Revenue, FY2010-FY15 (US$ Billions)
Figure 39: Novartis AG Revenue by Business Segment (FY2015)
Figure 40: Novartis AG Revenue, FY2011-FY2015 (US$ Billions)
Figure 41: Qiagen NV Revenue by Business Segment (FY2015)
Figure 42: Qiagen NV Revenue by Customer Classes (FY2015)
Figure 43: Qiagen NV Revenue, FY2011-FY2015 (US$ Billions)
Figure 44: Hologic Inc Revenue by Business Segments (2015)
Figure 45: Hologic Inc Revenue, FY2011-FY2015 (US$ Billions)

List of Tables:
Table 1: Major M&A in Diagnostics*
Table 2: Prominent NGS platforms, the sequencing technology, features and capabilities
Table 3: Cancer Care Cost by Cancer Site, 2010 and 2020E (US$)
Table 4: Summary for Recommendations and Evidence of US Screening Guidelines
Table 5: Global Molecular Diagnostics Market Players Capability Analysis
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Hologic Inc
  • Novartis AG
  • Qiagen NV
  • Roche Holdings
  • MORE
Molecular diagnostics is used for detecting patient’s susceptibility to a disease by tests for detecting and characterizing pathogenic mutations in DNA and RNA samples. It is the most dynamic segment of the global in vitro diagnostics market, given the advantages of precise genetic information over traditional tests. Molecular diagnostics in healthcare has been disseminating around the world at a robust growth rate due its unique ability to unlock molecular information of patients. The market has burgeoned in span of 25 years. It is further poised to reach new heights by breaching US$ 11 billion mark by 2022 by growing at a CAGR of 9.2% in the forecasted period 2016-22.

In terms of market structure, molecular diagnostics industry is classified into three broad categories - clinical infectious disease, genomics and blood donor screening. The clinical infectious disease segment has two sub-segments: virology and bacteriology tests. The genomics segment is further sub-divided into genetic diseases and disorders, cancer testing, HLA testing, and pharmacogenetic testing. Infectious diseases are the largest segment of molecular diagnostics market.

Growth of the industry is fuelled by prevalence of reproductive infectious diseases such as Chlamydia and Gonorrhea, surge in various types of oncology diagnostics, ageing population and government’s mandate on regular screening of HPV and CT/NG. However, complex regulatory framework and lack of clarity on reimbursement are the major factors restraining the growth of the molecular diagnostics market. Key trends prevailing in the industry includes rise in number of strategic industry alliances and use of Next Generation Sequencing (NGS) in clinical molecular diagnostics.

The report provides information on the current scenario, detailed market outlook of the molecular analysis market segments such as Infectious diseases with focus on Human Papilloma virus (HPV) in virology segment and Chlamydia and Gonorrhoea in bacteriology segment. It further analyzes genomics testing market with focus on Human Leukocyte Antigen (HLA) testing. Lastly, Blood Donor Screening market is analysed in the report. Future forecasts on all prominent application areas of the industry till 2022 is also provided in the report. Furthermore, key industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.

Major industry players operating in the market include Roche Holding AG, Novartis AG, Hologic Inc, Abbott Diagnostics, Becton Dickinson and Qiagen NV, among others. Roche Holdings, Novartis AG, Hologic Inc and Qiagen NV are profiled herein based on attributes such as business overview, product segments, financial and business strategies. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global molecular diagnostics market.
Note: Product cover images may vary from those shown
5 of 6
- Hologic Inc
- Novartis AG
- Qiagen NV
- Roche Holdings
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll